Plk1 phosphorylation of Orc2 and Hbo1 contributes to gemcitabine resistance in pancreatic cancer

Although gemcitabine is the standard chemotherapeutic drug for treatment of pancreatic cancer, almost all patients eventually develop resistance to this agent. Previous studies identified Polo-like kinase 1 (Plk1) as the mediator of gemcitabine resistance, but the molecular mechanism remains unknown...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Song, Bing, Liu, X. Shawn, Rice, Steven, Kuang, Shihuan, Elzey, Bennett D., Konieczny, Stephen F., Ratliff, Timothy L., Hazbun, Tony, Chiorean, Elena G., Liu, Xiaoqi
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2012
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3732037/
https://ncbi.nlm.nih.gov/pubmed/23188630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-12-0632
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg